KalVista Pharmaceuticals, Inc.
KALVNASDAQHealthcare● Active
$26.98
+$0.03(+0.09%)
Market Cap$1.4B
P/E Ratio—
52W High$26.98
52W Low$9.83
KalVista Pharmaceuticals, Inc. (KALV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KALV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.92
Est. -$0.38 · -144.5%
Revenue
$0.01B
Est. $0.04B · -64.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
KALV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Dec 3, 2026 | -$0.26 | — | — | — | $0.05B | — |
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.26 | — | — | — | $0.05B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.38 | -$0.92 | -144.5% | $0.01B | $0.04B | -64.9% |
| ▼ Q1 FY2026 | Mar 24, 2026 | -$0.54 | -$1.01 | -87.0% | $0.00B | $0.01B | -73.4% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.96 | -$0.92 | +4.2% | $0.01B | $0.03B | -57.6% |
| ▼ Q3 FY2025 | Sep 11, 2025 | -$0.91 | -$1.12 | -23.1% | $0.00B | $0.00B | +99.8% |
| ▼ Q3 FY2025 | Jul 10, 2025 | -$0.80 | -$0.99 | -23.9% | — | $0.00B | — |
| ▼ Q1 FY2025 | Mar 12, 2025 | -$0.89 | -$0.92 | -3.4% | — | $0.00B | — |
Q4 FY2026
Dec 3, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.92
EPS Est.
-$0.38
EPS Surpr.
-144.5%
Revenue
$0.01B
Q1 FY2026
Mar 24, 2026Miss
EPS Actual
-$1.01
EPS Est.
-$0.54
EPS Surpr.
-87.0%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.92
EPS Est.
-$0.96
EPS Surpr.
+4.2%
Revenue
$0.01B
Q3 FY2025
Sep 11, 2025Miss
EPS Actual
-$1.12
EPS Est.
-$0.91
EPS Surpr.
-23.1%
Revenue
$0.00B
Q3 FY2025
Jul 10, 2025Miss
EPS Actual
-$0.99
EPS Est.
-$0.80
EPS Surpr.
-23.9%
Revenue
—
Q1 FY2025
Mar 12, 2025Miss
EPS Actual
-$0.92
EPS Est.
-$0.89
EPS Surpr.
-3.4%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $-0.25 | $-0.20 | $-0.16 | 5 |
| Q1 FY2027 | $-0.08 | $-0.07 | $-0.06 | 3 |
| Q4 FY2026 | $-0.92 | $-0.23 | $0.25 | 8 |
| Q3 FY2026 | $-0.41 | $-0.26 | $-0.11 | 5 |
| Q2 FY2026 | $-0.41 | $-0.37 | $-0.34 | 5 |
| Q1 FY2026 | $-1.07 | $-0.67 | $-0.11 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.0B | $0.0B | $0.1B | 3 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q4 FY2026 | $0.0B | $0.1B | $0.1B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.1B | 4 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -144.5% | $26.76 | $26.73 | -0.11% |
| ▼ Q1 FY2026 | Mar 24, 2026 | -87.0% | $16.60 | $16.46 | -0.84% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +4.2% | $10.78 | $10.89 | +1.02% |
| ▼ Q3 FY2025 | Sep 11, 2025 | -23.1% | $15.39 | $14.81 | -3.77% |
| ▼ Q3 FY2025 | Jul 10, 2025 | -23.9% | $15.99 | $15.51 | -3.00% |
| ▼ Q1 FY2025 | Mar 12, 2025 | -3.4% | $12.43 | $12.45 | +0.16% |
| ▲ Q4 FY2024 | Dec 5, 2024 | +0.0% | $9.46 | $9.06 | -4.23% |
| ▲ Q3 FY2024 | Sep 5, 2024 | +8.4% | $12.92 | $12.87 | -0.39% |
Q2 FY2026-0.11%
Report Date
May 15, 2026
EPS Beat/Miss
-144.5%
Price Before
$26.76
Price After
$26.73
Q1 FY2026-0.84%
Report Date
Mar 24, 2026
EPS Beat/Miss
-87.0%
Price Before
$16.60
Price After
$16.46
Q4 FY2025+1.02%
Report Date
Nov 10, 2025
EPS Beat/Miss
+4.2%
Price Before
$10.78
Price After
$10.89
Q3 FY2025-3.77%
Report Date
Sep 11, 2025
EPS Beat/Miss
-23.1%
Price Before
$15.39
Price After
$14.81
Q3 FY2025-3.00%
Report Date
Jul 10, 2025
EPS Beat/Miss
-23.9%
Price Before
$15.99
Price After
$15.51
Q1 FY2025+0.16%
Report Date
Mar 12, 2025
EPS Beat/Miss
-3.4%
Price Before
$12.43
Price After
$12.45
Q4 FY2024-4.23%
Report Date
Dec 5, 2024
EPS Beat/Miss
+0.0%
Price Before
$9.46
Price After
$9.06
Q3 FY2024-0.39%
Report Date
Sep 5, 2024
EPS Beat/Miss
+8.4%
Price Before
$12.92
Price After
$12.87
Avg Beat Reaction-1.20%
Avg Miss Reaction-1.51%
Beat Rate3 / 8 quarters
Largest Move-4.23% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KALV ends December
KalVista Pharmaceuticals, Inc. (KALV) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.92 — missing the analyst consensus of $-0.38 by -144.5%. The next KALV earnings date is expected around September 1, 2026.
Each quarter, investors track KALV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KALV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KALV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KALV earnings · 5 questionsKalVista Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. KALV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KALV historically reports after market close (AMC).
KALV earnings datewhen is KALV earningsKALV next earnings datewhen does KALV report earningsKALV earnings calendar
▸ Source: FMP · KalVista Pharmaceuticals, Inc. SEC filings · US GAAP · KalVista Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026